JP2014507475A - シクロベンザプリンを使用してうつ病を処置するための方法および組成物 - Google Patents
シクロベンザプリンを使用してうつ病を処置するための方法および組成物 Download PDFInfo
- Publication number
- JP2014507475A JP2014507475A JP2013557811A JP2013557811A JP2014507475A JP 2014507475 A JP2014507475 A JP 2014507475A JP 2013557811 A JP2013557811 A JP 2013557811A JP 2013557811 A JP2013557811 A JP 2013557811A JP 2014507475 A JP2014507475 A JP 2014507475A
- Authority
- JP
- Japan
- Prior art keywords
- cyclobenzaprine
- pharmaceutical composition
- day
- depression
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 229960003572 cyclobenzaprine Drugs 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 6
- 229940005513 antidepressants Drugs 0.000 claims abstract description 6
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims description 15
- 239000010409 thin film Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000013270 controlled release Methods 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 6
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 208000001640 Fibromyalgia Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 239000000674 adrenergic antagonist Substances 0.000 description 4
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 4
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 4
- 229940125681 anticonvulsant agent Drugs 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000007897 gelcap Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001848 lamotrigine Drugs 0.000 description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 229940102566 valproate Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- UHLPYBQGKLHIFK-UWVJOHFNSA-N (11z)-11-[3-(dimethylamino)propylidene]dibenzo[1,3-e:1',2'-f][7]annulen-2-ol Chemical compound C1=CC2=CC=C(O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 UHLPYBQGKLHIFK-UWVJOHFNSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- GEGNHNIVXNHTJN-UHFFFAOYSA-N 1-chlorobutan-1-ol Chemical compound CCCC(O)Cl.CCCC(O)Cl GEGNHNIVXNHTJN-UHFFFAOYSA-N 0.000 description 1
- XECQQDXTQRYYBH-UHFFFAOYSA-N 3-(11-dibenzo[1,2-a:1',2'-e][7]annulenylidene)-N-methyl-1-propanamine Chemical compound C1=CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 XECQQDXTQRYYBH-UHFFFAOYSA-N 0.000 description 1
- CWVULMRJHWMZLY-UHFFFAOYSA-N 3-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)-n,n-dimethylpropan-1-amine oxide Chemical compound C1=CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 CWVULMRJHWMZLY-UHFFFAOYSA-N 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 101000855342 Homo sapiens Cytochrome P450 1A2 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000036992 Psychogenic pain disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 102000057459 human CYP1A2 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000008665 sleep physiology Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449838P | 2011-03-07 | 2011-03-07 | |
| US61/449,838 | 2011-03-07 | ||
| PCT/US2012/027926 WO2012122193A1 (en) | 2011-03-07 | 2012-03-06 | Methods and compositions for treating depression using cyclobenzaprine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016007041A Division JP2016053095A (ja) | 2011-03-07 | 2016-01-18 | シクロベンザプリンを使用してうつ病を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014507475A true JP2014507475A (ja) | 2014-03-27 |
| JP2014507475A5 JP2014507475A5 (cg-RX-API-DMAC7.html) | 2015-04-23 |
Family
ID=46796107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557811A Pending JP2014507475A (ja) | 2011-03-07 | 2012-03-06 | シクロベンザプリンを使用してうつ病を処置するための方法および組成物 |
| JP2016007041A Pending JP2016053095A (ja) | 2011-03-07 | 2016-01-18 | シクロベンザプリンを使用してうつ病を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016007041A Pending JP2016053095A (ja) | 2011-03-07 | 2016-01-18 | シクロベンザプリンを使用してうつ病を処置するための方法および組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11998516B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3682885A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2014507475A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2012225548B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2829200C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1122998T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2683245T4 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2773834T5 (cg-RX-API-DMAC7.html) |
| FI (1) | FI2683245T4 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20200142T4 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE048596T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2683245T (cg-RX-API-DMAC7.html) |
| PL (1) | PL2683245T5 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2683245T (cg-RX-API-DMAC7.html) |
| RS (1) | RS60240B2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2683245T2 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202000083T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012122193A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021505629A (ja) * | 2017-12-11 | 2021-02-18 | トニックス ファーマ ホールディングス リミテッド | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700578T1 (it) * | 2009-11-20 | 2018-01-11 | Tonix Pharma Holdings Ltd | Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| SG10201707528WA (en) | 2013-03-15 | 2017-10-30 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| WO2015150948A1 (en) * | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof |
| MY186047A (en) | 2014-09-18 | 2021-06-17 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| CN106890129A (zh) * | 2015-12-18 | 2017-06-27 | 健乔信元医药生技股份有限公司 | 环苄普林之延释剂型 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003506484A (ja) * | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用 |
| JP2003506483A (ja) * | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | シクロベンザプリンおよびその組成物による全般性不安障害の処置 |
| JP2007511611A (ja) * | 2003-11-19 | 2007-05-10 | テラコス・インコーポレイテッド | 肥満を処置するための薬物併用療法 |
| JP2009510080A (ja) * | 2005-09-28 | 2009-03-12 | サイプレス・バイオサイエンス・インコーポレーテッド | 線維筋痛症候群の長期治療のためのミルナシプラン |
| WO2009089494A2 (en) * | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3882246A (en) | 1971-05-21 | 1975-05-06 | Merck & Co Inc | Treatment of skeletal muscle disorders with cyclobenzaprine |
| US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| FR2635461B1 (fr) | 1988-08-18 | 1992-01-17 | Adir | Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| DK1077683T3 (da) | 1998-05-14 | 2003-03-31 | Alza Corp | Antidepressiv behandling |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| NZ532583A (en) | 2001-11-05 | 2006-12-22 | Krele Pharmaceuticals | Compositions and methods for increasing compliance using aldehyde dehydrogenase inhibitors ( ALDH ) such as disulfiram and monoamine oxidase B inhibitors ( MAOB ) such as selegiline |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| MXPA05004381A (es) | 2002-10-25 | 2006-02-10 | Collegium Pharmaceutical Inc | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
| US20050059656A1 (en) | 2003-04-07 | 2005-03-17 | Cornell Research Foundation, Inc. | Compositions and methods for protecting against mitochondria component-mediated pathology |
| NZ544162A (en) | 2003-05-29 | 2008-09-26 | Shire Llc | Abuse resistant amphetamine compounds |
| JP2007510642A (ja) | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| JP2007516259A (ja) | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
| EP1715853A4 (en) | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
| TW200531680A (en) | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
| US20090069267A1 (en) | 2006-01-17 | 2009-03-12 | Abrams Daniel J | Central administration of stable formulations of therapeutic agents for cns conditions |
| US20080146672A1 (en) | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
| ES2431570T3 (es) | 2007-05-07 | 2013-11-27 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención |
| WO2009002770A1 (en) | 2007-06-22 | 2008-12-31 | Merck & Co., Inc. | 6.5-pyrrolopiperidine tachykinin receptor antagonists |
| AU2008279091A1 (en) | 2007-07-23 | 2009-01-29 | Biotie Therapies, Inc | Treatment of post-traumatic stress disorder |
| US20090060983A1 (en) | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| WO2009058950A2 (en) | 2007-10-30 | 2009-05-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| US8586103B2 (en) | 2008-02-08 | 2013-11-19 | Foresee Pharmaceuticals, Llc | Non-polymeric compositions for controlled drug delivery |
| US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
| JP5380909B2 (ja) | 2008-05-30 | 2014-01-08 | 株式会社ブリヂストン | 金型及び樹脂発泡成形品の成形方法 |
| US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
| US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| US8807979B2 (en) | 2009-09-24 | 2014-08-19 | Mcneil-Ppc, Inc. | Machine for the manufacture of dosage forms utilizing radiofrequency energy |
| SMT201700578T1 (it) | 2009-11-20 | 2018-01-11 | Tonix Pharma Holdings Ltd | Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US20130165511A1 (en) | 2010-09-01 | 2013-06-27 | TONIX Pharmaceuticals Holding Corp | Treatment for cocaine addiction |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| ITMI20110558A1 (it) | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| MX382516B (es) | 2012-06-15 | 2025-03-13 | Tonix Pharmaceuticals Inc | Composiciones y metodos para absorcion transmucosa. |
| EP3369730B1 (en) | 2012-11-05 | 2020-08-05 | Emory University | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto |
| SG10201707528WA (en) | 2013-03-15 | 2017-10-30 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| AU2015289389A1 (en) | 2014-07-18 | 2017-09-14 | Medipath, Inc. | Compositions and methods for physiological delivery using Cannabidiol |
| MY186047A (en) | 2014-09-18 | 2021-06-17 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| SG11202004799TA (en) | 2017-12-11 | 2020-06-29 | Tonix Pharma Holdings Ltd | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| IL317836A (en) | 2022-06-21 | 2025-02-01 | TONIX Pharmaceuticals Holding Corp | Cyclobenzaprine therapy for acute sequelae of (SARS)-CoV-2 infection (PASC) |
-
2012
- 2012-03-05 US US13/412,571 patent/US11998516B2/en active Active
- 2012-03-06 PL PL12755254.5T patent/PL2683245T5/pl unknown
- 2012-03-06 CA CA2829200A patent/CA2829200C/en active Active
- 2012-03-06 ES ES12755254T patent/ES2773834T5/es active Active
- 2012-03-06 FI FIEP12755254.5T patent/FI2683245T4/fi active
- 2012-03-06 WO PCT/US2012/027926 patent/WO2012122193A1/en not_active Ceased
- 2012-03-06 SM SM20200083T patent/SMT202000083T1/it unknown
- 2012-03-06 EP EP19214568.8A patent/EP3682885A1/en not_active Withdrawn
- 2012-03-06 DK DK12755254.5T patent/DK2683245T4/da active
- 2012-03-06 PT PT127552545T patent/PT2683245T/pt unknown
- 2012-03-06 LT LTEP12755254.5T patent/LT2683245T/lt unknown
- 2012-03-06 SI SI201231736T patent/SI2683245T2/sl unknown
- 2012-03-06 AU AU2012225548A patent/AU2012225548B2/en active Active
- 2012-03-06 HR HRP20200142TT patent/HRP20200142T4/hr unknown
- 2012-03-06 JP JP2013557811A patent/JP2014507475A/ja active Pending
- 2012-03-06 EP EP12755254.5A patent/EP2683245B2/en active Active
- 2012-03-06 HU HUE12755254A patent/HUE048596T2/hu unknown
- 2012-03-06 RS RS20200155A patent/RS60240B2/sr unknown
-
2016
- 2016-01-18 JP JP2016007041A patent/JP2016053095A/ja active Pending
- 2016-08-31 AU AU2016222412A patent/AU2016222412B2/en active Active
-
2018
- 2018-06-26 AU AU2018204633A patent/AU2018204633C1/en active Active
-
2020
- 2020-02-05 CY CY20201100112T patent/CY1122998T1/el unknown
- 2020-06-11 AU AU2020203874A patent/AU2020203874B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003506484A (ja) * | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用 |
| JP2003506483A (ja) * | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | シクロベンザプリンおよびその組成物による全般性不安障害の処置 |
| JP2007511611A (ja) * | 2003-11-19 | 2007-05-10 | テラコス・インコーポレイテッド | 肥満を処置するための薬物併用療法 |
| JP2009510080A (ja) * | 2005-09-28 | 2009-03-12 | サイプレス・バイオサイエンス・インコーポレーテッド | 線維筋痛症候群の長期治療のためのミルナシプラン |
| WO2009089494A2 (en) * | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021505629A (ja) * | 2017-12-11 | 2021-02-18 | トニックス ファーマ ホールディングス リミテッド | 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020203874B2 (en) | Methods and compositions for treating depression using cyclobenzaprine | |
| US10722478B2 (en) | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine | |
| DK2501234T3 (en) | METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE | |
| HK1252658A1 (zh) | 治疗炎症或神经性疼痛的方法 | |
| JP6853791B2 (ja) | パーキンソン病及び関連する障害の治療における使用のための組成物 | |
| US20150157575A1 (en) | Pharmaceutical Formulations Comprising Vilazodone | |
| CN101257907A (zh) | 左旋佐匹克隆和抗抑郁剂的组合 | |
| WO2022094230A1 (en) | Compounds for treating psychosis or depression | |
| NZ614725B2 (en) | Methods and compositions for treating depression using cyclobenzaprine | |
| NZ714294B2 (en) | Methods And Compositions For Treating Depression Using Cyclobenzaprine | |
| Sequeira | Central nervous system stimulants, drugs that suppress appetite, and drugs used in Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150305 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150305 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150715 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150717 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151113 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160610 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160704 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20160805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170713 |